Absence of PKR Attenuates the Anti-HSV-1 Activity of an Adenoviral Vector Expressing Murine IFN-β
- 1 August 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 22 (8) , 861-871
- https://doi.org/10.1089/107999002760274872
Abstract
A study was undertaken to evaluate the efficacy of an adenoviral vector containing the murine interferon-β (IFN-β) transgene (Ad:IFN-β) against herpes simplex virus type 1 (HSV-1) infection in two transduced cell lines. The transduction of the adenoviral vector efficiency, ranging from 2% to 100%, was dependent on the multiplicity of infection (moi) (0.4-50 plaque-forming units [pfu]/cell). Supernatants from cells transduced with the Ad:IFN-β but not the adenoviral null vector (Ad:Null) contained biologically active IFN-β (6.6-106 U/ml depending on the moi). Cells transduced with the Ad:IFN-β displayed up to 25-fold reduction in viral titers compared with cells transduced with the Ad:Null or nontransduced cell controls. The suppression in viral titer correlated with a reduction in viral gene (α, β, and γ) and protein expression. The expression of IFN β-responsive genes, including protein kinase R (PKR) and 2′,5′-oligoadenylate synthetase (OAS), were significantly elevated in the Ad:IFN-β-transduced cells by 12-fold and 25-fold, respectively. However, after infection with HSV-1, a transient but significant drop in PKR but not OAS gene expression was observed 10 h postinfection. The absence of PKR but not RNase L significantly attenuated the antiviral efficacy of the transgene. Collectively, these results illustrate the feasibility of employing a viral vector to deliver a potent antiviral gene to targeted cells without any obvious detriment to the vector itself and support an important role for PKR as a mediator of the anti-HSV-1 activity of type I IFN.Keywords
This publication has 34 references indexed in Scilit:
- ICP0, ICP4, or VP16 Expressed from Adenovirus Vectors Induces Reactivation of Latent Herpes Simplex Virus Type 1 in Primary Cultures of Latently Infected Trigeminal Ganglion CellsJournal of Virology, 2001
- Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirusPublished by Wolters Kluwer Health ,2001
- Immune responses limit adenovirally mediated gene expression in the adult mouse eyeGene Therapy, 1998
- High throughput method for creating and screening recombinant adenovirusesGene Therapy, 1998
- Recalcitrant Molluscum Contagiosum in a Patient with AIDS Successfully Treated by a Combination of CO 2 -laser and Natural Interferon Beta GelActa Dermato-Venereologica, 1998
- Herpes Simplex VirusesClinical Infectious Diseases, 1998
- Antiviral Activity of Autocrine Interferon-β Requires the Presence of a Functional Interferon Type I ReceptorJournal of Interferon & Cytokine Research, 1995
- A herpes simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivoArchiv für die gesamte Virusforschung, 1994
- Development of Methods for Somatic Cell Gene Therapy Directed Against Viral Diseases, Using Retroviral Vectors Carrying the Murine or Human Interferon-β Coding Sequence: Establishment of the Antiviral State in Human CellsHuman Gene Therapy, 1993
- Resolution of acute hepatitis C after therapy with natural beta interferonThe Lancet, 1991